Neuropathic Pain Drug Market worth $23.01 billion by 2030, growing at a CAGR of 9.93% - Exclusive Report by 360iResearch

The "Neuropathic Pain Drug Market by Type (Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy), Treatment (Antidepressant Drugs Type, Multimodal Therapy, NSAIDs Type), Indication, Distribution, End User - Global Forecast 2024-2030" report has been added to 360iResearch.com's offering.

The Global Neuropathic Pain Drug Market to grow from USD 11.85 billion in 2023 to USD 23.01 billion by 2030, at a CAGR of 9.93%.

Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/neuropathic-pain-drug?utm_source=openpr&utm_medium=referral&utm_campaign=sample

The neuropathic pain drug includes pharmaceutical products designed to alleviate or manage pain caused by damaged nerves. This neuropathic pain drug comprises various medications such as antidepressants, anticonvulsants, local anesthetics, cannabinoids, and opioids and extends to prescription and over-the-counter drugs available through hospitals, pharmacies, clinics, and online platforms worldwide. The rising prevalence of diseases associated with neuropathic pain, such as diabetes mellitus and an aging population more susceptible to chronic pain conditions, are key factors driving the need for neuropathic pain drugs. Additionally, increased awareness of effective treatment options among healthcare professionals and patients has led to better diagnosis rates and higher demand for these medications. Advancements in pharmacological research have improved the understanding of neuropathic pain mechanisms and identified novel therapeutic targets. This progress has resulted in a strong pipeline of potential new therapies that could further bolster market growth. However, the neuropathic pain drug market also faces challenges, such as the lack of universally effective treatments due to significant variations among patients' experiences with neuropathic pain. Stringent regulatory requirements for drug approval add more time and cost to research and development processes. Investing in research & development efforts focused on novel therapeutic targets or more efficient drug delivery systems. Next-generation therapies such as gene therapy or personalized medicine approaches are promising in providing tailored treatments catering to individual patient profiles.

In America, the rising geriatric population coupled with a high incidence of diabetes-induced peripheral neuropathy is expected to propel growth in this market. The United States showcases a considerable aging population and people suffering from neurological disorders, further creating demand for effective drugs. In APAC, emerging economies such as China, India, and Japan are experiencing rapid increases in healthcare expenditure and heightened awareness about neuropathic pain management. The APAC region also has a significant prevalence of diabetic patients globally, creating the need for effective drugs and therapeutics. EMEA presents a diverse landscape regarding healthcare infrastructure and disease prevalence; however, it still exhibits substantial scope for market expansion due to its well-established healthcare system in the European region, increased R&D investments from major pharmaceutical companies, and favorable reimbursement policies.

Market Segmentation & Coverage:

This research report categorizes the Neuropathic Pain Drug Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy, and Trigeminal Neuralgia. The Trigeminal Neuralgia is projected to witness significant market share during forecast period.

Based on Treatment, market is studied across Antidepressant Drugs Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type is further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type is further studied across Ibuprofen and Naproxen. The Multimodal Therapy is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Diabetic Neuropathy and Spinal Stenosis. The Diabetic Neuropathy is projected to witness significant market share during forecast period.

Based on Distribution, market is studied across Online Pharmacies and Retail Pharmacies & Drug Stores. The Retail Pharmacies & Drug Stores is projected to witness significant market share during forecast period.

Based on End User, market is studied across Clinics and Hospitals. The Clinics is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/neuropathic-pain-drug?utm_source=openpr&utm_medium=referral&utm_campaign=inquire

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Neuropathic Pain Drug Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Neuropathic Pain Drug Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Neuropathic Pain Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Aptinyx Inc., Assertio Holdings, Inc., Astellas Pharma Inc., AstraZeneca PLC, Axsome Therapeutics, Inc., Bausch Health Companies Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, CARA THERAPEUTICS, INC., Daiichi Sankyo Company, Limited, Eli Lilly and Company, GlaxoSmithKline PLC, Grünenthal Group, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Scilex Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Trevena Inc., and Vertex Pharmaceuticals Incorporated.

Key Topics Covered:

1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Neuropathic Pain Drug Market, by Type
7. Neuropathic Pain Drug Market, by Treatment
8. Neuropathic Pain Drug Market, by Indication
9. Neuropathic Pain Drug Market, by Distribution
10. Neuropathic Pain Drug Market, by End User
11. Americas Neuropathic Pain Drug Market
12. Asia-Pacific Neuropathic Pain Drug Market
13. Europe, Middle East & Africa Neuropathic Pain Drug Market
14. Competitive Landscape
15. Competitive Portfolio

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Neuropathic Pain Drug Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Neuropathic Pain Drug Market?
3. What is the competitive strategic window for opportunities in the Neuropathic Pain Drug Market?
4. What are the technology trends and regulatory frameworks in the Neuropathic Pain Drug Market?
5. What is the market share of the leading vendors in the Neuropathic Pain Drug Market?
6. What modes and strategic moves are considered suitable for entering the Neuropathic Pain Drug Market?

Read More @ https://www.360iresearch.com/library/intelligence/neuropathic-pain-drug?utm_source=openpr&utm_medium=referral&utm_campaign=analyst

Contact 360iResearch

Mr. Ketan Rohom
Sales & Marketing,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
sales@360iresearch.com
+1-530-264-8485
+91-922-607-7550

About 360iResearch

360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.

We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset - our people.

Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.

Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.

This release was published on openPR.